AR008799A1 - Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento - Google Patents

Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento

Info

Publication number
AR008799A1
AR008799A1 ARP970103502A ARP970103502A AR008799A1 AR 008799 A1 AR008799 A1 AR 008799A1 AR P970103502 A ARP970103502 A AR P970103502A AR P970103502 A ARP970103502 A AR P970103502A AR 008799 A1 AR008799 A1 AR 008799A1
Authority
AR
Argentina
Prior art keywords
composition
treatment
prophylaxis
prevent
treat malaria
Prior art date
Application number
ARP970103502A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR008799A1 publication Critical patent/AR008799A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion de vacuna que se emplea en la prevencion o tratamiento del paludismo, que comprende de numerosos antígenos derivados del paludismo encombinacion con un adyuvante, preferentemente un estimulador de la respuesta celular THI.También se propone la utilizacion de dicha vacuna para lapreparacion de medicamentos y métodos terapéuticos o preventivos aplicando dicha composicion.
ARP970103502A 1996-08-02 1997-08-01 Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento AR008799A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9616351.4A GB9616351D0 (en) 1996-08-02 1996-08-02 Vaccine composition

Publications (1)

Publication Number Publication Date
AR008799A1 true AR008799A1 (es) 2000-02-23

Family

ID=10797980

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970103502A AR008799A1 (es) 1996-08-02 1997-08-01 Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento

Country Status (32)

Country Link
US (2) US20020172692A1 (es)
EP (2) EP1623720A3 (es)
JP (1) JP2000517295A (es)
KR (1) KR20000029747A (es)
CN (1) CN1241639C (es)
AP (1) AP1166A (es)
AR (1) AR008799A1 (es)
AT (1) ATE394119T1 (es)
AU (1) AU706303B2 (es)
BG (1) BG63290B1 (es)
BR (1) BR9710913A (es)
CA (1) CA2262402A1 (es)
CO (1) CO4650186A1 (es)
CZ (1) CZ290826B6 (es)
DE (1) DE69738672D1 (es)
DZ (1) DZ2283A1 (es)
EA (1) EA002167B1 (es)
GB (1) GB9616351D0 (es)
ID (1) ID17860A (es)
IL (1) IL128318A (es)
MA (1) MA24291A1 (es)
MY (1) MY116128A (es)
NO (1) NO319844B1 (es)
OA (1) OA10969A (es)
PE (1) PE97298A1 (es)
PL (1) PL188741B1 (es)
SK (1) SK282438B6 (es)
TR (1) TR199900195T2 (es)
UA (1) UA68336C2 (es)
UY (1) UY24654A1 (es)
WO (1) WO1998005355A1 (es)
ZA (1) ZA976815B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
JP4628958B2 (ja) * 2003-12-01 2011-02-09 明治乳業株式会社 アンジオテンシン変換酵素阻害ペプチド
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
NZ565512A (en) * 2005-08-02 2011-08-26 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
SG173377A1 (en) * 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
GB0614254D0 (en) * 2006-07-18 2006-08-30 Smithkline Beecham Biolog Vaccine
PL2066344T3 (pl) 2006-09-07 2011-10-31 Glaxosmithkline Biologicals Sa Skojarzona szczepionka zawierająca inaktywowany wirus polio
UY31285A1 (es) 2007-08-13 2009-03-31 Vacunas
CA2708716A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
UY31574A1 (es) * 2007-12-24 2009-08-03 Vacunas contra la malaria
EP2313108A4 (en) * 2008-06-30 2013-06-12 Us Army As Represented By The Secretary Of The Army ANTIPALUDE VACCINE OF SELF-ASSEMBLED POLYPEPTIDE NANOPARTICLES
AU2010315868B2 (en) * 2009-11-05 2012-12-20 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum sporozoite and liver stage antigens
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals Sa métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP3980044A1 (en) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponin purification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071705B1 (en) * 1981-05-21 1989-11-23 The Wellcome Foundation Limited Protozoal antigen
ES8800273A1 (es) * 1985-03-28 1987-11-01 Univ New York Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9012580D0 (en) * 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
FR2679776A1 (fr) * 1991-07-31 1993-02-05 Pasteur Institut Melange de constituants peptidiques ayant des proprietes vaccinantes contre le paludisme, notamment du a plasmodium falciparum.
DE69228698T2 (de) * 1991-11-16 1999-09-16 Smithkline Beecham Biologicals S.A., Rixensart HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
US6169171B1 (en) * 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
JP3755890B2 (ja) * 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM368994A0 (en) * 1994-02-04 1994-02-24 Saramane Pty Ltd Malaria merozoite antigen subunit vaccine
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
FR2744723A1 (fr) * 1996-02-14 1997-08-14 Pasteur Institut Proteine recombinante contenant un fragment c-terminal d'une proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

Also Published As

Publication number Publication date
CN1231613A (zh) 1999-10-13
BG63290B1 (bg) 2001-09-28
CZ29299A3 (cs) 1999-06-16
IL128318A (en) 2002-04-21
SK11599A3 (en) 2000-03-13
EA002167B1 (ru) 2002-02-28
SK282438B6 (sk) 2002-02-05
AP9901448A0 (en) 1999-03-31
ATE394119T1 (de) 2008-05-15
US20060292170A1 (en) 2006-12-28
IL128318A0 (en) 2000-01-31
UY24654A1 (es) 2001-08-27
NO990464L (no) 1999-02-01
ID17860A (id) 1998-01-29
KR20000029747A (ko) 2000-05-25
DZ2283A1 (fr) 2002-12-25
BG103141A (en) 1999-08-31
AP1166A (en) 2003-06-30
US20020172692A1 (en) 2002-11-21
NO319844B1 (no) 2005-09-19
EA199900069A1 (ru) 1999-10-28
CZ290826B6 (cs) 2002-10-16
WO1998005355A1 (en) 1998-02-12
AU4204097A (en) 1998-02-25
PL188741B1 (pl) 2005-04-29
EP1623720A2 (en) 2006-02-08
UA68336C2 (en) 2004-08-16
MY116128A (en) 2003-11-28
CO4650186A1 (es) 1998-09-03
TR199900195T2 (xx) 1999-04-21
EP1623720A3 (en) 2006-02-22
PL331424A1 (en) 1999-07-19
CN1241639C (zh) 2006-02-15
OA10969A (en) 2003-03-04
ZA976815B (en) 1998-05-11
NO990464D0 (no) 1999-02-01
DE69738672D1 (de) 2008-06-19
PE97298A1 (es) 1999-02-14
GB9616351D0 (en) 1996-09-11
AU706303B2 (en) 1999-06-10
MA24291A1 (fr) 1998-04-01
BR9710913A (pt) 1999-08-17
JP2000517295A (ja) 2000-12-26
EP0957933A1 (en) 1999-11-24
CA2262402A1 (en) 1998-02-12
EP0957933B1 (en) 2008-05-07

Similar Documents

Publication Publication Date Title
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
ES2196024T3 (es) Vacunas conjugadas de gangliosido-klh con qs-21.
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
PT1024824E (pt) Composicao de vacina dispersivel solida para administracao oral
BG104092A (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
ES2177535T3 (es) Vacunas contra protozoos intestinales.
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
NO20012634L (no) Nye kreftbehandlinger
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
PT1076561E (pt) Terapia de combinacao para o tratamento de tumores
ES2171233T3 (es) Uso de eliprodil para la preparacion de un medicamento para el tratamiento de trastornos isquemicos de la retina o el nervio optico.
AR010568A1 (es) Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori
ES2158857T3 (es) Vacunas a base de estreptoquinasa.
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
NO970185L (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
YU37402A (sh) Vakcina za lečenje upale prostate i benigne prostatne hiperplazije, koja obuhvata sojeve lactobacillus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal